Interestingly, the correlation between poor prognosis and EB1 overexpression in tumors applies to other cancers, such as esophageal cell carcinoma, breast cancer, gastric adenocarcinoma, colorectal cancer, and glioblastoma [6–10]. This evidence concerns the gene MAPRE1 and breast cancer.